Similar articles

• Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.

  Ganz PA, Hussey MA, Moinpour CM, Unger JM, Hutchins LF, Dakhil SR, Giguere JK, Goodwin JW, Martino S, Albain KS. Ganz PA, et al. J Clin Oncol. 2008 Mar 10;26(8):1223-30. doi: 10.1200/JCO.2007.11.8877. Epub 2008 Jan 28. J Clin Oncol. 2008. PMID: 18227530 Clinical Trial.
• The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.

  Dang C, Fornier M, Sugarman S, Troso-Sandoval T, Lake D, D'Andrea G, Seidman A, Sklarin N, Dickler M, Currie V, Gilewski T, Moynahan ME, Drullinsky P, Robson M, Wasserheit-Leiblich C, Mills N, Steingart R, Panageas K, Norton L, Hudis C. Dang C, et al. J Clin Oncol. 2008 Mar 10;26(8):1216-22. doi: 10.1200/JCO.2007.12.0733. J Clin Oncol. 2008. PMID: 18323546 Clinical Trial.
• New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.

  Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK. Ryberg M, et al. J Natl Cancer Inst. 2008 Aug 6;100(15):1058-67. doi: 10.1093/jnci/djn206. Epub 2008 Jul 29. J Natl Cancer Inst. 2008. PMID: 18664656
• Evolving concepts in the systemic adjuvant treatment of breast cancer.

  Bonadonna G. Bonadonna G. Cancer Res. 1992 Apr 15;52(8):2127-37. Cancer Res. 1992. PMID: 1559216 Review. No abstract available.
• [Significance of cytostatic drug dose in adjuvant chemotherapy of breast carcinoma].

  Thomssen C. Thomssen C. Geburtshilfe Frauenheilkd. 1996 Jul;56(7):M102-5. Geburtshilfe Frauenheilkd. 1996. PMID: 8964443 Review. German. No abstract available.